Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial

Leukemia

Volumn 27, Issue 1, 2013, Pages 41-47

  Jenkinson, S ^a   Koo, K ^a   Mansour, M R ^a,h   Goulden, N ^b   Vora, A ^c   Mitchell, C ^d   Wade, R ^e   Richards, S ^e   Hancock, J ^f   Moorman, A V ^g   Linch, D C ^a   Gale, R E ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e CLINICAL TRIAL SERVICE UNIT   (United Kingdom)

^f SOUTHMEAD HOSPITAL   (United Kingdom)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

FBXW7; NOTCH1; risk stratification; T ALL

Indexed keywords

ASPARAGINASE; DAUNORUBICIN; DEXAMETHASONE; FBXW7 PROTEIN; MEMBRANE RECEPTOR; NOTCH1 RECEPTOR; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CHILD; DISEASE COURSE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; INTENSIVE CARE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; T CELL LEUKEMIA;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CELL CYCLE PROTEINS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DAUNORUBICIN; DEXAMETHASONE; DNA, NEOPLASM; F-BOX PROTEINS; FEMALE; GENOTYPE; HUMANS; INFANT; MALE; MUTATION; POLYMERASE CHAIN REACTION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECEPTOR, NOTCH1; REMISSION INDUCTION; SURVIVAL RATE; UBIQUITIN-PROTEIN LIGASES; VINCRISTINE; YOUNG ADULT;

EID: 84873567134     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.176     Document Type: Article

References (33)

1. Herold R, von Stackelberg A, Hartmann R, Eisenreich B, Henze G. Acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group (ALL-REZ BFM) experience: early treatment intensity makes the difference. J Clin Oncol 2004; 22: 569-570.
2. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. New Engl J Med 2006; 354: 166-178.
3. Paganin M, Ferrando A. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev 2011; 25: 83-90.
4. Koch U, Radtke F. Notch in T-ALL: new players in a complex disease. Trends Immunol 2011; 32: 434-442.
5. Hansson EM, Lendahl U, Chapman G. Notch signaling in development and disease. Semin Cancer Biol 2004; 14: 320-328.
6. Mumm JS, Kopan R. Notch signaling: from the outside in. Dev Biol 2000; 228: 151-165.
7. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-271.
8. Zuurbier L, Homminga I, Calvert V, te Winkel ML, Buijis-Gladdines JG, Kooi C et al. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia 2010; 24: 2014-2022.
9. Breit S, Stanulla M, Flohr T, Schrappe M, Ludwig WD, Tolle G et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 2006; 108: 1151-1157.
10. Clappier E, Collette S, Grardel N, Girard S, Suarez L, Brunie G et al. NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia 2010; 24: 2023-2031.
11. Park MJ, Taki T, Oda M, Watanabe T, Yumura-Yagu K, Kobayashi R et al. FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol 2009; 145: 198-206.
12. Mansur MB, Hassan R, Barbosa TC, Splendore A, Jotta PY, Yunes JA et al. Impact of complex NOTCH1 mutations on survival in paediatric T-cell leukaemia. BMC Cancer 2012; 12: 9.
13. Sanchez-Irizarry C, Carpenter AC, Weng AP, Pear WS, Aster JC, Blacklow SC. Notch subunit heterodimerization and prevention of ligand-independent proteolytic activation depend, respectively, on a novel domain and the LNR repeats. Mol Cell Biol 2004; 24: 9265-9273.
14. Gupta-Rossi N, Le Bail O, Gonen H, Brou C, Logeat F, Six E et al. Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor. J Biol Chem 2001; 276: 34371-34378.
15. Sulis ML, Williams O, Palomero T, Tosello V, Pallikuppam S, Real PJ et al. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood 2008; 112: 733-740.
16. Gordon WR, Roy M, Vardar-Ulu D, Garfinkel M, Mansour MJ, Aster JC et al. Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL. Blood 2009; 113: 4381-4390.
17. Chiang MY, Xu L, Shestova O, Histen G, L'Heureux S, Romany C et al. Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest 2008; 118: 3181-3194.
18. Malyukova A, Dohda T, von der Lehr N, Akhoondi S, Corcoran M, Heyman M et al. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res 2007; 67: 5611-5616.
19. Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, Basso G et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 2007; 204: 1825-1835.
20. Kox C, Zimmermann M, Stanulla M, Leible S, Schrappe M, Ludwig WD et al. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia 2010; 24: 2005-2013.
21. O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gammasecretase inhibitors. J Exp Med 2007; 204: 1813-1824.
22. Jen KY, Song IY, Banta KL, Wu D, Mao JH, Balmain A. Sequential mutations in Notch1, Fbxw7, and Tp53 in radiation-induced mouse thymic lymphomas. Blood 2012; 119: 805-809.
23. Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007; 447: 966-971.
24. Erbilgin Y, Sayitoglu M, Hatirnaz O, Dogru O, Akcay A, Tuysuz G et al. Prognostic significance of NOTCH1 and FBXW7 mutations in pediatric T-ALL. Dis Markers 2010; 28: 353-360.
25. Qureshi A, Mitchell C, Richards S, Vora A, Goulden N. Asparaginase-related venous thrombosis in UKALL 2003-re-exposure to asparaginase is feasible and safe. Br J Haematol 2010; 149: 410-413.
26. Goulden NJ, Knechtli CJ, Garland RJ, Langlands K, Hancock JP, Potter MN et al. Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia. Br J Haematol 1998; 100: 235-244.
27. Ferrando A. NOTCH mutations as prognostic markers in T-ALL. Leukemia 2010; 24: 2003-2004.
28. Remke M, Pfister S, Kox C, Toedt G, Becker N, Benner A et al. High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. Blood 2009; 114: 1053-1062.
29. Rudner LA, Brown KH, Dobrinski KP, Bradley DF, Garcia MI, Smith AC et al. Shared acquired genomic changes in zebrafish and human T-ALL. Oncogene 2011; 30: 4289-4296.
30. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157-163.
31. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101-105.
32. Kridel R, Meissner B, Rogic S, Boyle M, Telenius A, Woolcock B et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 2012; 119: 1963-1971.
33. Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011; 208: 1389-1401.